Ocuphire Pharma Results Presentation Deck

LO 5 ZETA-1 Trial: Key Takeaways APX3330 achieved statistical significance on a key pre-specified secondary endpoint of preventing clinically meaningful progression of diabetic retinopathy (as defined by binocular 3 or more steps worsening on the DRSS¹) after 24 weeks of treatment Trend toward more efficacy at 24 weeks vs 12 weeks, suggests that the 52-week Phase 3 trial may generate a larger signal due to an increase in % of placebo subjects who progress Prevention of 3-step worsening (binocular) is a suitable endpoint for an oral, systemically drug ➜ Ocuphire plans to go forward with this potential registration endpoint in Phase 3 following confirmation with the FDA in EOP2 meeting Oral APX3330 demonstrated favorable safety and tolerability Retinal KOLs feedback suggest that slowing of DR progression with an oral agent would be a useful treatment in patients with background DR and good visual function If approved, APX3330 could be an important new primary preventative therapeutic option that could be used in a large number of diabetic patients who are earlier in their disease 1. diabetic retinopathy severity score Source: ZETA-1 Clinical Trial Ocuphire

View entire presentation